Fused tricyclic compounds as adenosine receptor antagonist

A compound represented by Formula I

• or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, wherein:
• — represents a single bond or a double bond;
• X is selected from O, S or NRa;
• Y1 is selected from N or CH;
• Y2 is selected from NR5, O or CR5R6;
• Y3 is selected from N, CH, CH2, C(═O) or C(═S);
• Y4 is selected from N, C or CH;
• Rl and R2 are independently selected from hydrogen or alkyl;
• R3 is —A—Z—B—Q;
• wherein, A is absent or is a group selected from alkylene, alkenylene or alkynylene;
• wherein one or more methylene groups is optionally replaced by hetero atoms or groups selected from the group consisting of —O—, —S(O)p—, —N(Ra)—, or —C(O);
• alkylene, alkenylene and alkynylene is optionally substituted with —(CRdRe),OR7, (CRdRe)nCOOR7, —(CRdRe)nNR8R9, cyano, halogen, haloalkyl, perhaloalkyl, alkoxyalkoxy, alkyl or cycloalkyl;
• Z is absent or is selected from a cycloalkyl or a heterocyclyl;
• wherein cycloalkyl and heterocyclyl are unsubstituted or substituted independently with 1, 2, or 3 substituents independently selected from alkyl, alkenyl, alkynyl, acyl, —(CRdRe)nOR7, (CRdRe)nCOOR7, —(CRdRe)nNR8R9, aminocarbonyl, alkoxycarbonylamino, halogen, haloalkyl, perhaloalkyl, azido, cyano, keto, thiocarbonyl, —SO3H, aminocarbonylamino, nitro, —S(O)2NRaRa, —NRbS(O)2Rb or —S(O)pRc;
• B is absent or is a group selected from alkylene, alkenylene or alkynylene;
• wherein one or more methylene groups is optionally replaced by hetero atoms or groups selected from the group consisting of —O—, —S(O)p—, —N(Ra)—, or —C(O);
• alkylene, alkenylene and alkynylene is optionally substituted with hydroxy, amino, aminoalkyl, cyano, halogen, haloalkyl, perhaloalkyl, carboxy, carboxyalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, alkoxyalkoxy or alkyl;
• Q is selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl;
• wherein alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl are unsubstituted or substituted independently with 1, 2, or 3 substituents independently selected from alkyl, alkenyl, alkynyl, halogen, haloalkyl, perhaloalkyl, azido, cyano, nitro, keto, thiocarbonyl, cyanoalkyl, cyanoalkylcarbonyl, —(CRdRe)n)OR7, —(CRdRe)nC(O)R7, —(CRdRe)nSR7, —(CRdRe)nCOOR7, —(CRdRe)nNR8R9, —(CRdRe)nC(O)NR8R9, —(CRdRe)nNR8C(O)OR7, —(CRdRe)nNR8C(O)NR8R9, —NRbS(O)2Rb, —S(O)pRc, —SO3H, —S(O)2NRaRa, cycloalkyl, cycloalkenyl, cycloalkylalkyl aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl;
• wherein each substituent is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, amino, substituted amino, cyano or —S(O)pRc;
• R4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl;
• wherein alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, arylalkyl, aryl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl are unsubstituted or substituted independently with up to four substituents independently selected from alkyl, alkenyl, alkynyl, acyl, —(CRdRe)nOR7, (CRdRe),COOR7, —(CRdRe)nNR8R9, aminocarbonyl, alkoxycarbonylamino, aminocarbonylamino, azido, cyano, halogen, haloalkyl, perhaloalkyl, keto, nitro, —S(O)2NRbRb, —NRbS(O)2Rb or —S(O)pRc, thiocarbonyl, —SO3H, cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocyclyl ;
• R5 and R6 are independently selected from the group consisting of hydrogen, hydroxy, —(CRdRe)nOR7, (CRdRe)nCOOR7, —(CRdRe)nNR8R9, cyanoalkyl, haloalkyl, alkoxyalkoxyalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl;
• R7 is selected from hydrogen, alkyl, halogen, haloalkyl, carbonylamino, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
• R8 and R9 are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, —(CRdRe)nOR7, —(CRdRe)nC(O)R7, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl, Or
• R8 and R9 taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally have additional heteroatoms selected from O, N or S, said ring system is further optionally substituted with 1 to 4 substituents independently selected from halo, alkyl, alkenyl, alkynyl, nitro, cyano, —(CRdRe)nOR7, —(CRdRe)nSR7, —(CRdRe)nNR8R9, oxo, alkylsulfonyl, —(CRdRe)nCOOR7, —(CRdRe)nC(O)NR8R9, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• Ra is selected from hydrogen or alkyl;
• Rb at each occurrence is independently selected from the group consisting of hydrogen, alkyl, acyl, carboxyalkyl, carbonylamino, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl;
• Rc is selected from alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl;
• Rd and Re are independently selected from the group consisting of hydrogen, —OR7, halogen, haloalkyl, perhaloalkyl and alkyl;
• n is 0, 1, 2, 3 or 4 and
• p is 0, 1 or 2.